- Trials with a EudraCT protocol (157)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
157 result(s) found for: Brain Infection.
Displaying page 1 of 8.
EudraCT Number: 2004-002714-11 | Sponsor Protocol Number: EORTC 22033-26033 | Start Date*: 2005-06-06 | |||||||||||
Sponsor Name:European Organisation for Research and Treatment of Cancer | |||||||||||||
Full Title: Primary chemotherapy with temozolomide vs. radiotherapy in patients with low grade gliomas after stratification for genetic 1p loss: a phase III study | |||||||||||||
Medical condition: Histologically proven low-grade glioma ♦ Astrocytoma WHO grade II (gemistocytic, fibrillary and protoplasmatic) ♦ Oligoastrocytoma WHO grade II ♦ Oligodendroglioma WHO grade II | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: AT (Completed) DE (Completed) GB (Completed) IT (Completed) DK (Prematurely Ended) BE (Completed) ES (Completed) PT (Completed) HU (Completed) SE (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-002845-39 | Sponsor Protocol Number: Infmed1 | Start Date*: 2019-10-02 | |||||||||||
Sponsor Name:Aalborg University Hospital | |||||||||||||
Full Title: Partial oral antibiotic treatment for bacterial brain abscess: An open-label randomised non-inferiority trial (ORAL) | |||||||||||||
Medical condition: Brain abscess | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-000083-24 | Sponsor Protocol Number: GCPL/RGN/02 | Start Date*: 2007-06-07 | |||||||||||
Sponsor Name:Regen Therapeutics PLC | |||||||||||||
Full Title: A survey of efficacy of zolpidem in patients with brain injury including SPECT brain scans in selected patients | |||||||||||||
Medical condition: Brain damage of any original cause, such as strokes, trauma, birth injury, post-viral infection. | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Not Authorised) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-001166-26 | Sponsor Protocol Number: M13-813 | Start Date*: 2015-12-28 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Randomized, Placebo Controlled Phase 3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor R... | |||||||||||||
Medical condition: Newly diagnosed glioblastoma (GBM) or gliosarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) NL (Completed) IE (Completed) DE (Completed) BE (Completed) AT (Completed) GB (GB - no longer in EU/EEA) PT (Completed) ES (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-018421-19 | Sponsor Protocol Number: PASS | Start Date*: 2010-05-05 | ||||||||||||||||
Sponsor Name:AMC | ||||||||||||||||||
Full Title: Preventive Antibiotics in Stroke Study | ||||||||||||||||||
Medical condition: Stroke and stroke-associated infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-004301-27 | Sponsor Protocol Number: NIBIT-M2 | Start Date*: 2012-11-08 | |||||||||||
Sponsor Name:FONDAZIONE NIBIT | |||||||||||||
Full Title: A randomized, Phase III study of Fotemustine versus the Combination of Fotemustine and Ipilimumab in Patients with Metastatic Melanoma with brain metastasis | |||||||||||||
Medical condition: Subjects (men and women) 18 years old presenting with Stage IV melanoma with presence of brain metastasis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-004692-19 | Sponsor Protocol Number: 963 | Start Date*: 2007-12-19 | |||||||||||
Sponsor Name:Biotest AG | |||||||||||||
Full Title: Prevention of congenital cytomegalovirus infection in infants of mothers with primary cytomegalovirus infection during pregnancy. A randomised, open, controlled, multicentre and multinational study... | |||||||||||||
Medical condition: Congenital CMV infection after primary CMV infection during pregnancy | |||||||||||||
|
|||||||||||||
Population Age: In utero, Newborns, Infants and toddlers, Children, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) HU (Completed) AT (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002758-29 | Sponsor Protocol Number: mdb/001 | Start Date*: 2012-05-04 |
Sponsor Name:Med. Univ. Wien, Uk für Innere Medizin I | ||
Full Title: Cerebral microdialysis in neurointensive care patients to determine brain penetration of antibiotics. An open label explorative study. | ||
Medical condition: Cerebral microdialysis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2019-004007-12 | Sponsor Protocol Number: 066VER | Start Date*: 2020-06-02 |
Sponsor Name:University of Sussex | ||
Full Title: Brain connectivity and patient reported outcomes in people with HIV (PWH) with symptoms of insomnia switching integrase inhibitor-based ART; a randomised controlled study | ||
Medical condition: HIV infection | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2006-000518-19 | Sponsor Protocol Number: 106672;106673;106675;106679;-80 | Start Date*: 2006-04-05 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||
Full Title: A Phase III, open, multicentre study to assess the long-term persistence of a booster dose of GSK Biologicals? Hib-MenC conjugate vaccine compared to a booster dose of Infanrix? hexa (combined diph... | ||||||||||||||||||
Medical condition: The prevention of invasive diseases caused by Haemophilus influenzae type b and Neisseria meningitidis serogroup C. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-004802-70 | Sponsor Protocol Number: APHP200491 | Start Date*: 2021-08-03 |
Sponsor Name:Assistance Publique – Hôpitaux de Paris | ||
Full Title: Impact of post-ARDS COVID sedation on late neuroinflammation | ||
Medical condition: All patients who have developed and survived ARDS linked to COVID-19 infection, admitted to intensive care units, meeting the study's inclusion criteria may be included in this research. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2012-005641-21 | Sponsor Protocol Number: 112148 | Start Date*: 2015-05-26 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||
Full Title: A phase III, open, controlled study to assess the persistence of antibodies after one dose of GlaxoSmithKline Biologicals’ meningococcal serogroup ACWY conjugate vaccine (MenACWY-TT) given intramus... | ||||||||||||||||||
Medical condition: Prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W and/or Y | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2020-005827-35 | Sponsor Protocol Number: RC31/20/0441 | Start Date*: 2021-03-25 |
Sponsor Name:University Hospital of Toulouse | ||
Full Title: SARS-CoV-2 neurotropism, micRoglial ActivatioN and cytokine dySregulaTiOn in COVID-19 patients with delirium | ||
Medical condition: delirium | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2005-006066-34 | Sponsor Protocol Number: 105987,105988 | Start Date*: 2015-06-01 | |||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||||||||||||
Full Title: A phase III, single-blind, randomized, controlled, multinational study for the evaluation of safety of GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-t... | |||||||||||||||||||||||
Medical condition: Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-005032-26 | Sponsor Protocol Number: 106445, | Start Date*: 2015-06-25 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||||||||||||
Full Title: A phase III, open, randomized, controlled, multi-centre study to demonstrate the non-inferiority of the meningococcal serogroup C and the Haemophilus influenzae type b immune response of GlaxoSmith... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (for primary immunization against meningococcal serogroup C and booster immunization against Haemophilus influenzae type b diseases of healthy children aged 12-18 months) | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-004427-31 | Sponsor Protocol Number: TAFCNS2015 | Start Date*: 2016-03-07 |
Sponsor Name:Gothenburg University | ||
Full Title: Tenofovir Alafenamide Fumarate (TAF) effect on residual intrathecal immune activation | ||
Medical condition: HIV-infection in the central nervous system | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-002410-36 | Sponsor Protocol Number: 115524 | Start Date*: 2012-07-10 | |||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | |||||||||||||
Full Title: A phase III, open, controlled study to evaluate immunogenicity of GSK Biologicals’ MenACWY-TT conjugate vaccine administered intramuscularly to at risk subjects from 1 to less than 18 years and to ... | |||||||||||||
Medical condition: Meningococcal infection | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-004778-84 | Sponsor Protocol Number: 116775 | Start Date*: 2014-03-13 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||
Full Title: A Phase IIIb, open-label, multi-centric study to evaluate the immunogenicity of one dose of GSK Biologicals’ MenACWY-TT conjugate vaccine administered intramuscularly in healthy adolescents aged 10... | ||||||||||||||||||
Medical condition: Healthy subjects (active immunisation of individuals from the age of 12 months against invasive meningococcal diseases caused by Neisseria meningitidis serogroup A, C, W-135 and Y). | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Prematurely Ended) ES (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-002997-35 | Sponsor Protocol Number: OVG2014/05 | Start Date*: 2015-02-06 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: A phase III multi-centre randomised, double blind, placebo controlled trial to assess the role of intravenous immunoglobulin in the management of children with encephalitis (The IgNiTE study) | |||||||||||||
Medical condition: Encephalitis | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002719-24 | Sponsor Protocol Number: 112021 | Start Date*: 2015-06-01 | ||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||
Full Title: A phase II, open, multi-center study to evaluate the long-term anti-body persistence at 1 year, 3 years and 5 years after the administration of one or two doses of GlaxoSmithKline (GSK) Biologicals... | ||||||||||||||||||
Medical condition: Invasive disease caused by Neisseria meningitidis serogroups A, C W-135 and Y | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.